399 related articles for article (PubMed ID: 21421631)
1. Statin myopathy: significant problem with minimal awareness by clinicians and no emphasis by clinical investigators.
Whayne TF
Angiology; 2011 Jul; 62(5):415-21. PubMed ID: 21421631
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic options for aggressive low-density lipoprotein cholesterol lowering: benefits versus risks.
McKenney JM
Am J Cardiol; 2005 Aug; 96(4A):60E-66E. PubMed ID: 16098846
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular risk reduction: what do recent trials with rosuvastatin tell us?
Fabbri G; Maggioni AP
Adv Ther; 2009 May; 26(5):469-87. PubMed ID: 19444394
[TBL] [Abstract][Full Text] [Related]
4. The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis.
Harper CR; Jacobson TA
Curr Opin Lipidol; 2007 Aug; 18(4):401-8. PubMed ID: 17620856
[TBL] [Abstract][Full Text] [Related]
5. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER)--can C-reactive protein be used to target statin therapy in primary prevention?
Mora S; Ridker PM
Am J Cardiol; 2006 Jan; 97(2A):33A-41A. PubMed ID: 16442935
[TBL] [Abstract][Full Text] [Related]
6. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study.
Strandberg TE; Feely J; Sigurdsson EL;
Clin Ther; 2004 Nov; 26(11):1821-33. PubMed ID: 15639694
[TBL] [Abstract][Full Text] [Related]
7. Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin.
Gazi IF; Daskalopoulou SS; Nair DR; Mikhailidis DP
Curr Med Res Opin; 2007 Sep; 23(9):2183-92. PubMed ID: 17692154
[TBL] [Abstract][Full Text] [Related]
8. Pooled analyses of effects on C-reactive protein and low density lipoprotein cholesterol in placebo-controlled trials of ezetimibe monotherapy or ezetimibe added to baseline statin therapy.
Pearson TA; Ballantyne CM; Veltri E; Shah A; Bird S; Lin J; Rosenberg E; Tershakovec AM
Am J Cardiol; 2009 Feb; 103(3):369-74. PubMed ID: 19166691
[TBL] [Abstract][Full Text] [Related]
9. Neuromuscular complications of statins.
Ahn SC
Phys Med Rehabil Clin N Am; 2008 Feb; 19(1):47-59, vi. PubMed ID: 18194749
[TBL] [Abstract][Full Text] [Related]
10. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
Wlodarczyk J; Sullivan D; Smith M
Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019
[TBL] [Abstract][Full Text] [Related]
11. Managing statin-induced muscle toxicity in a lipid clinic.
Blaier O; Lishner M; Elis A
J Clin Pharm Ther; 2011 Jun; 36(3):336-41. PubMed ID: 21414023
[TBL] [Abstract][Full Text] [Related]
12. Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe.
Daskalopoulou SS; Mikhailidis DP
Curr Med Res Opin; 2006 Mar; 22(3):511-28. PubMed ID: 16574035
[TBL] [Abstract][Full Text] [Related]
13. Predicting benefit from statins by C-reactive protein, LDL-cholesterol or absolute cardiovascular risk.
Stewart RA
Future Cardiol; 2009 May; 5(3):231-6. PubMed ID: 19656039
[TBL] [Abstract][Full Text] [Related]
14. Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.
Bennett S; Sager P; Lipka L; Melani L; Suresh R; Veltri E;
J Womens Health (Larchmt); 2004 Dec; 13(10):1101-7. PubMed ID: 15650343
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study).
Ballantyne CM; Weiss R; Moccetti T; Vogt A; Eber B; Sosef F; Duffield E;
Am J Cardiol; 2007 Mar; 99(5):673-80. PubMed ID: 17317370
[TBL] [Abstract][Full Text] [Related]
16. Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.
Glueck CJ; Aregawi D; Agloria M; Khalil Q; Winiarska M; Munjal J; Gogineni S; Wang P
Clin Ther; 2006 Jun; 28(6):933-42. PubMed ID: 16860175
[TBL] [Abstract][Full Text] [Related]
17. Pleiotropic effects of statins: evidence against benefits beyond LDL-cholesterol lowering.
Pedersen TR
Am J Cardiovasc Drugs; 2010; 10 Suppl 1():10-7. PubMed ID: 21391729
[TBL] [Abstract][Full Text] [Related]
18. Optimal low-density lipoprotein cholesterol lowering--morning versus evening statin administration.
Plakogiannis R; Cohen H
Ann Pharmacother; 2007 Jan; 41(1):106-10. PubMed ID: 17200427
[TBL] [Abstract][Full Text] [Related]
19. Effects of ubiquinone (coenzyme Q10) on myopathy in statin users.
Schaars CF; Stalenhoef AF
Curr Opin Lipidol; 2008 Dec; 19(6):553-7. PubMed ID: 18957876
[TBL] [Abstract][Full Text] [Related]
20. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
